Diabetes is the third commonest chronic illness in children following asthma and epilepsy. More recently the overall prevalence of diabetes in children and adults continued to increase dramatically. In children, this has partially been contributed to by the pandemic of obesity. Understandably, this posed an economic burden on health authorities and countries dealing with significant morbidity of the disease with potentially serious complications. In parallel to this, more therapeutic discoveries expanded the list of choice for available medications. We hypothesize that specialist clinicians are requested by an authority to submit a report of prioritization for anti-diabetic drugs. The authority new policy is to purchase for only three of anti-diabetic medications among a long list of old and new drugs. We gave a recommendation here in response to this request based on different properties of these medications and also based on the largest known clinical trials in the field. Some may have a different choice for a third medication besides insulin and metformin and physicians in many clinical settings may have a choice of more than three at a time. However, we, at least, provide here a thorough review of these drugs, their mechanistic of action, benefits and side effects to facilitate a better choice for individual patients according to underlying pathophysiological cause, other medical needs and tolerance to different medications. Paediatricians are increasingly managing adolescents with type 2 diabetes these days. Hence, we wrote this review as quick reference guidance to anti-diabetic medications to which they might be less familiar.